2-[4-fluoro-3-[[2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]acetic acid
C17H16F4N4O2 — CID 156549973
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[4-fluoro-3-[[2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]acetic acid
2-[4-fluoro-3-[[2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]acetic acid (PubChem CID 156549973) has the molecular formula C17H16F4N4O2 and a molecular weight of 384.33 g/mol. Its IUPAC name is 2-[4-fluoro-3-[[2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]acetic acid.
Molecular Properties
| Compound Name | 2-[4-fluoro-3-[[2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]acetic acid |
|---|---|
| PubChem CID | 156549973 |
| Molecular Formula | C17H16F4N4O2 |
| Molecular Weight | 384.33 g/mol |
| Exact Mass | 384.12 |
| IUPAC Name | 2-[4-fluoro-3-[[2-[(2S)-2-methylazetidin-1-yl]-6-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]acetic acid |
| SMILES | C[C@H]1CCN1c1nc(Nc2cc(CC(=O)O)ccc2F)cc(C(F)(F)F)n1 |
| InChI | InChI=1S/C17H16F4N4O2/c1-9-4-5-25(9)16-23-13(17(19,20)21)8-14(24-16)22-12-6-10(7-15(26)27)2-3-11(12)18/h2-3,6,8-9H,4-5,7H2,1H3,(H,26,27)(H,22,23,24)/t9-/m0/s1 |
| InChIKey | DITWQFHTROJEBZ-VIFPVBQESA-N |
| XLogP | 3.60 |
| TPSA | 78.35 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 384.33 |
| LogP ≤ 5 | 3.60 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156549973 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.